ALTSTATION.IO

GE HealthCare Technologies Inc. (GEHC) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$82.30

Change

-0.01%

Market Cap

$37.51B

Avg Volume

3.6M

Company Overview

GE HealthCare Technologies Inc. develops and sells a wide range of medical devices, imaging equipment, and healthcare solutions. Their products include CT scanners, MRI machines, X-ray systems, and ultrasound technologies. They serve hospitals, clinics, and healthcare providers globally, providing essential tools for the diagnosis, treatment, and monitoring of various medical conditions. Their portfolio also spans digital solutions and pharmaceutical diagnostics, essential for enhancing patient care across different medical fields.

GE HealthCare is a market leader in medical devices, with strong competition from firms like Siemens Healthineers, Philips, and Canon Medical. Their edge comes from a diverse product range and established brand reputation in imaging and patient care solutions. However, the sector faces challenges like pricing pressures, rapid technological advancements, and increasing competition from smaller, specialized firms. Keeping pace with innovation and cost-effective solutions is vital for maintaining their leadership position.

Currently, GE HealthCare is in a growth phase, largely driven by the increased demand for advanced imaging and patient monitoring solutions. They’ve made significant strides in expanding their digital offerings and enhancing the integration of artificial intelligence in their products. Recent milestones include strategic partnerships and investments aimed at advancing their technology in predictive diagnostics and personalized medicine, positioning them well for future opportunities in the evolving healthcare landscape.

Key Financials

Market Cap

$37.51B

Revenue

$20.63B

EBITDA

$3.64B

Gross Margin

40.0%

Profit Margin

10.1%

Revenue Growth

7.1%

Total Cash

$4.49B

Total Debt

$10.46B

Free Cash Flow

$1.69B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

18.09

Forward P/E

14.78

Beta

1.23

52-Week High

$94.80

52-Week Low

$57.65

EPS

$4.55

50-Day Avg

$82.55

200-Day Avg

$75.72

Price/Book

3.61

Technical Analysis

The overall trend for GE HealthCare Technologies Inc. (GEHC) over the past 52 weeks has been bearish, with a significant decline from the peak around $92 in late February to the current price of $82.30, reflecting a 7.7% drop. Key resistance is noted near the $90 mark, where the price struggled to maintain momentum in early March and again in February. Support appears to be established at approximately $80.65, which coincides with recent price action, indicating it has held up against downward pressure in the last few weeks. A noticeable price pattern includes a series of lower highs and lower lows, particularly from March through June, followed by a consolidation period with fluctuations between $70 and $85. Recent momentum has shown some weakness, with minor recovery attempts failing to sustain beyond the $85 level, suggesting cautious trader sentiment. The current price of $82.30 sits above the established support but significantly lower than its 52-week high of $92, indicating potential for further downward testing if bearish pressure continues.

Recent News and Developments

Here are the latest news and developments for GE HealthCare Technologies Inc

(GEHC) stock in the past week:

Market Update

### GE HealthCare Exceeds Q4 Expectations and Provides Strong 2026 Outlook

Market Update

GE HealthCare (GEHC) announced fourth-quarter 2025 results that surpassed analyst estimates and provided an optimistic outlook for fiscal year 2026. The company forecasted an adjusted profit per share in the range of $4.95 to $5.15, exceeding the consensus analyst estimate of $4.92 per share, driven by robust demand for its diagnostic and imaging devices. Organic revenue growth for 2026 is project

Market Sentiment and Analyst Recommendations

Bull Case

GEHC just beat Q4 expectations and raised 2026 guidance to $4.95-$5.15 EPS, above the $4.92 consensus. The Allia Moveo system just cleared FDA and CE Mark approval, opening a new revenue stream in interventional imaging across cardiovascular, vascular, and surgical procedures. At 18.09x forward P/E with 7.1% revenue growth and $4.49B in cash against $10.46B debt, the valuation isn’t stretched relative to healthcare equipment peers. Analysts have raised targets post-earnings, with Stifel moving to $98 and BTIG to $91, suggesting the market hasn’t fully priced in execution. The stock is only down 7.7% from its $94.80 high despite the bearish 52-week chart, meaning it’s holding support at $80.65 and could easily reach $93-98 if 2026 guidance converts.

Bear Case

The 52-week chart tells the real story: lower highs and lower lows from March through June with weak momentum that hasn’t sustained above $85. Revenue growth of 7.1% is respectable but not exceptional for a medical device company, and guidance for 3-4% organic growth in 2026 is actually a deceleration. Debt sits at $10.46B against only $4.49B in cash, leaving limited flexibility if margins compress or demand softens. The stock has already recovered 4.8% this week on earnings, so much of the good news is baked in. If GEHC fails to execute on Allia Moveo commercialization or guidance misses, the stock could test the $70-75 range given the weak technical setup.

What to Watch

Monitor Allia Moveo adoption rates starting in Q1 2026 earnings calls. The system’s commercial traction will be critical to justify the analyst enthusiasm and differentiate GEHC from competitors. Watch the 3-4% organic growth guidance for 2026 closely; if the company reports below 3% in Q1, expect downward revisions. Key resistance sits at $90; a break above that level with volume would signal real momentum and validate the bull thesis. Track debt reduction progress and free cash flow conversion; management needs to prove they can delever while funding R&D. The next earnings report (likely April/May 2026) will determine whether recent analyst target raises hold or get walked back. Watch for any competitive threats in interventional imaging or margin pressure in core diagnostic equipment segments.

Analyst Consensus

BUY

Based on 20 analyst opinions

Low Target

$77.00

Mean Target

$93.10

High Target

$108.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

54,000

Earnings & Dividends

Next Earnings

Apr 29, 2026

EPS (Trailing)

$4.55

Dividend Yield

17.0%

Payout Ratio

3.1%

Frequently Asked Questions

Is GEHC a good stock to buy?

Yes, analysts recommend GE HealthCare Technologies with a “BUY” rating and a target price of $93.10. This represents a potential upside of approximately 13.1% from the current price of $82.30.

What is GEHC’s price target?

The target price for GE HealthCare is set at $93.10. This target reflects positive sentiment and growth expectations in the healthcare and medical devices sector.

Does GEHC pay a dividend?

Yes, GE HealthCare offers a substantial dividend yield of 17.0%. This makes it an attractive option for income-focused investors.

What is GEHC’s P/E ratio?

GE HealthCare has a P/E ratio of 18.09 and a forward P/E of 14.78. These figures suggest the stock is reasonably valued relative to future earnings growth prospects.

How has GEHC performed in the last year?

GE HealthCare’s stock has seen a 52-week range from $57.65 to $94.80. The current price suggests strong performance and market confidence, particularly since it remains near its high for the year.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.